Nasdaq: AGEN) announced today the election of Samuel D.
patents gives ImClone and Abbott, a strong proprietary position for RCR technology worldwide," stated Samuel D.
The claims against all defendants would be dismissed with prejudice but the Company would retain the right to continue to pursue certain claims against its former chief executive officer, Samuel D.
3 million, an amount representing the withholding tax liability attributable to Samuel D.
ImClone Systems Incorporated (NASDAQ:IMCL), today announced that Samuel D.
and European clinical trial data," stated Samuel D.
We will be working closely with the FDA toward the goal of an expeditious acceptance of our BLA," stated Samuel D.
We are very pleased to join the ranks of the world's most impressive entrepreneurial companies," commented Samuel D.
The timely accomplishment of this most important milestone is a reflection of the Company's commitment to bring this very important product candidate to patients as quickly as possible," stated Samuel D.